Quick Answer
KalVista Pharmaceuticals, Inc. reported Cash And Cash Equivalents At Carrying Value of $131.62 million for the year ending 2025.
- KalVista Pharmaceuticals, Inc. showed an increase of +314.0% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from KalVista Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on July 10, 2025.
- XBRL data for this metric is available from 2012 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2012 to 2025), KalVista Pharmaceuticals, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 1,496.9%.
- Historical annual values: Fiscal year 2025: $131.62 million | Fiscal year 2024: $31.79 million | Fiscal year 2023: $56.24 million | Fiscal year 2022: $30.73 million | Fiscal year 2021: $50.59 million | Fiscal year 2020: $15.79 million | Fiscal year 2019: $32.01 million | Fiscal year 2018: $51.06 million | Fiscal year 2017: $30.95 million | Fiscal year 2016: $21.76 million | Fiscal year 2015: $53.72 million | Fiscal year 2015: $2.53 million | Fiscal year 2014: $3.90 million | Fiscal year 2014: $481.0 thousand | Fiscal year 2013: $9.78 million | Fiscal year 2012: $8.24 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: